Immix Biopharma Inc. (NASDAQ:IMMX) saw an upside of 9.44% to $1.97 after adding $0.17on Wednesday. The 5-day average trading volume is 198,173 shares of the company’s common stock. It has gained $2.0000 in the past week and touched a new high 4 times within the past 5 days. An average of 88,953 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 126,929.
IMMX’s 1-month performance is -3.90% or -$0.1500 on its low of $1.5500 reached on 08/17/23. The company’s shares have touched a 52-week low of $0.68 and high of $3.29, with the stock’s rally to the 52-week high happening on 02/06/23. YTD, IMMX has lost -13.97% or -$0.3600 and has reached a new high 5 times. However, the current price is down -40.12% from the 52-week high price.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
IMMX stock has a beta of 0.22. Moving on to other valuation ratios, the price-to-book (PB) in the most recent quarter is 2.24.
Immix Biopharma Inc.’s quick ratio for the period ended June 29 was 6.50, with the current ratio over the same period at 6.50. The firm’s gross profit as reported stood at $1000.0 against revenue of $8.22 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 46.37% to -$2.48 million, while revenue of -$3.8 million was -53.23% off the previous quarter. Analysts expected IMMX to announce -$0.17 per share in earnings in its latest quarter, but it posted -$0.24, representing a -41.20% surprise. EBITDA for the quarter stood at more than -$3.72 million. Shareholders hold equity totaling $16.29 million.
Let’s look briefly at Immix Biopharma Inc. (IMMX) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 22 August was 52.09% to suggest the stock is trending Neutral, with historical volatility in this time period at 111.99%.
The stock’s 5-day moving average is $1.8120, reflecting a +9.04% or $0.1600 change from its current price. IMMX is currently trading -5.39% above its 20-day SMA, +12.21% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -3.98% and SMA200 by+105.28%.
Stochastic %K and %D was 69.45% and 55.90% and the average true range (ATR) pointed at 0.1641. The RSI (14) points at 48.58%, while the 14-day stochastic is at 76.00% with the period’s ATR at 0.1618. The stock’s 9-day MACD Oscillator is pointing at 0.0844 and 0.0343 on the 14-day charts.
Analyst Ratings
Analysts offering their rating for IMMX stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate IMMX as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 2 have offered a “buy” rating.
What is IMMX’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $8.00 and a high of $14.00, with their median price target at $11.00. Looking at these predictions, the average price target given by analysts is for Immix Biopharma Inc. (IMMX) stock is $11.00.
